physics-based-simulation
(2)
Schrödinger Spent 30 Years Teaching Computers Chemistry. Now It Wants Every Lab to Predict Before It Pours.
The molecular-software veteran has a blunt pitch for modern R&D: compute first, synthesize less. Its own numbers show both the leverage of that idea and the expensive limits of prediction.
Huafeng Xu
Huafeng Xu is the founder and CEO of Fathom Therapeutics (formerly AtomMap), a New York drug-design company that simulates protein motion at atomic resolution to design small molecules that work inside living cells. A computational chemist with 25+ years and 10,000+ citations, Xu spent 12 years at D. E. Shaw Research building the free-energy and molecular-dynamics methods now standard across pharma, then served as CTO of Silicon Therapeutics and Roivant Discovery before launching his own company. In April 2026 Fathom closed an oversubscribed $47M Series A led by Sutter Hill Ventures to scale its Microcosmos engine.